Azienda Ospedaliero Universitaria Parma

At Azienda Ospedaliero Universitaria Parma, the strongest research activity centers on medical oncology, with a broad focus on solid tumors and blood cancers. Trials are studying major diseases such as non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, and multiple forms of leukemia and lymphoma, aiming to improve treatment effectiveness and expand options for patients with advanced or hard-to-treat disease.

• Studies in non-small cell lung cancer and small cell lung cancer are testing new targeted and immune-based therapies.
• Research in breast cancer, gastric cancer, and urothelial cancer is evaluating more effective treatment strategies.
• Trials in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma focus on improving disease control and patient outcomes.

These studies reflect a major oncology program with a strong emphasis on finding better therapies for both common and rare cancers.

This site also has an active portfolio in nephrology and related metabolic disease research. Trials address chronic kidney disease, IgA nephropathy, kidney transplant rejection, and diabetic kidney disease, with the goal of slowing disease progression, protecting kidney function, and improving transplant outcomes.

• Research in IgA nephropathy and chronic kidney disease is focused on better disease control and kidney preservation.
• Transplant studies examine outcomes after kidney transplantation in highly sensitized patients and those at risk of graft complications.
• Metabolic studies explore therapies for type 2 diabetes and kidney-related complications.

These trials combine kidney-focused care with broader efforts to improve long-term health in patients with complex medical conditions.

Clinical trials in cardiovascular disease at the Department of Medical Oncology include work on myocardial infarction, atherosclerotic cardiovascular disease, heart failure, stroke prevention, and venous thromboembolism. The main purpose is to test treatments that may reduce major cardiovascular events and improve protection after acute or chronic disease.

• Studies are evaluating prevention of ischemic stroke and other thrombotic complications.
• Research in myocardial infarction and atherosclerosis aims to lower future cardiovascular risk.
• Trials in heart failure and related metabolic conditions are exploring ways to improve long-term outcomes.

These investigations support a growing interest in cardiovascular risk reduction alongside cancer and kidney research.

Beyond cancer and organ disease, the site is involved in studies of multiple sclerosis, psoriasis, asthma, and other immune-mediated disorders. The research is aimed at improving symptom control, reducing inflammation, and testing whether newer therapies can offer better disease management than current standard care.

• Trials in multiple sclerosis are examining options for relapsing disease and progressive forms.
• Studies in psoriasis focus on improving skin symptoms in patients with higher body weight.
• Research in asthma and respiratory tract infections looks at better control of breathing-related illness.

This area shows the site’s interest in immune, neurologic, and respiratory conditions that affect quality of life and daily functioning.

The research portfolio at Azienda Ospedaliero Universitaria Parma includes important studies in pediatric oncology and other rare diseases. Trials cover acute lymphoblastic leukemia in children, lymphoblastic lymphoma, Langerhans cell histiocytosis, and rare tumors such as ependymoma and medulloblastoma, with the aim of improving survival and reducing long-term complications.

• Children’s cancer studies focus on refining treatment for acute lymphoblastic leukemia and related lymphoid cancers.
• Rare disease research includes Langerhans cell histiocytosis and uncommon brain tumors.
• These trials often seek better disease control while limiting later health effects.

Such work highlights the site’s role in advancing care for younger patients and for conditions that require specialized expertise.

The site is also contributing to diagnostic research and precision medicine, especially in oncology. Studies are evaluating imaging approaches, biomarker-guided strategies, and tests based on ctDNA or tumor characteristics to improve detection, guide treatment selection, and better match patients with the most appropriate therapy.

• Imaging research is exploring more accurate ways to detect and stage tumors.
• Biomarker-driven trials use ctDNA and molecular findings to guide treatment decisions.
• These studies support more personalized care in breast cancer, colon cancer, and other solid tumors.

This precision-focused work complements the broader therapeutic research program and reflects a strong interest in improving diagnosis as well as treatment.